ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.
| Revenue (TTM) | $30.68M |
| Gross Profit (TTM) | $12.37M |
| EBITDA | $7.05M |
| Operating Margin | 26.90% |
| Return on Equity | 2.57% |
| Return on Assets | 6.25% |
| Revenue/Share (TTM) | $3.39 |
| Book Value | $3.46 |
| Price-to-Book | 2.88 |
| Price-to-Sales (TTM) | 2.93 |
| EV/Revenue | 3.066 |
| EV/EBITDA | 25.87 |
| Quarterly Earnings Growth (YoY) | 259.90% |
| Quarterly Revenue Growth (YoY) | 11.50% |
| Shares Outstanding | $9.08M |
| Float | $6.03M |
| % Insiders | 32.00% |
| % Institutions | 20.30% |
Volatility is currently contracting
ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.
ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027.
PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026.
PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended June 30, 2026 after the market closes on Thursday, August 13, 2026. The Company is planning to host a conference call and webcast on August 14, 2026, at 9:00 AM ET to review the unaudited financial results.
ImmuCell's main value driver is First Defense. In my view, this is their core franchise and has real commercial momentum across year-round dairy customers. They've also shown improving manufacturing yields and redirected Re-Tain assets towards First Defense's production capacity. My main concern with ICCC is that it's heavily reliant on two main distributors, as well as concentrated on First Defense as its main product.
ICCC reports an 11.5% rise in preliminary Q2 sales, driven by robust U.S. demand and improved product availability, extending the momentum from its strong Q1 performance.
PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the second quarter of 2026. “Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025, driven by a 27.7% increase in domestic sales compared to 2025,” said Timothy Fiori, Chief Financial Officer of ImmuCell.
ImmuCell's premium valuation is backed by rising output, First Defense share gains and a sizable untapped calf-health market opportunity.
ICCC posts record Q1 sales and 34% earnings growth as demand for its First Defense calf-health products boosts margins and market share.
ImmuCell NASDAQ: ICCC reported a record first quarter of 2026, with management saying the company's narrowed focus on its First Defense calf scours prevention portfolio helped drive its first-ever quarter above $10 million in product sales.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ICCC and any ticker you trade — then tracks every position and per-strategy win rate.
